Cupid Limited: Soaring to New Heights with Record Q3 FY26 Performance

Cupid Limited, a diversified Indian healthcare and consumer products company, has announced a stellar performance for the third quarter of Fiscal Year 2026 (Q3 FY26), marking it as the strongest quarter in the company's history. The company reported a remarkable 101.71% year-on-year (YoY) growth in revenue from operations, reaching ₹93.50 crore, and an even more impressive 196.26% YoY surge in net profit, which stood at ₹32.83 crore. This exceptional growth is attributed to disciplined execution, robust demand across all business segments, and sustained momentum.

The company's total income for Q3 FY26 climbed to ₹104.38 crore, a 105.64% increase from ₹50.76 crore in Q3 FY25. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw a significant jump of 201.27% YoY, reaching ₹34.30 crore. This strong financial showing positions Cupid Limited for what management expects to be its strongest fiscal year yet, with confidence in exceeding the FY26 revenue guidance of ₹335 crore and a net profit exceeding ₹100 crore.

Strategic Growth Drivers and Operational Excellence

Cupid's performance is underpinned by a balanced growth model that leverages its strong global B2B export presence alongside a rapidly expanding domestic and international Fast-Moving Consumer Goods (FMCG) platform. The export-led B2B business continues to be a core strength, supported by multi-year international programs, global certifications, and a proven execution track record. The company's WHO/UNFPA prequalification and USFDA CE certifications create high entry barriers, enabling participation in regulated global tenders across over 125 countries.

Domestically, the FMCG portfolio is witnessing growing acceptance, driven by continuous product additions in personal care and wellness categories, coupled with an expanding retail footprint. Recently launched products like Petroleum Jelly, Face Wash, and Talcum Powder have received encouraging consumer response. The diagnostics (IVD) business is also gaining significant traction, emerging as a key long-term growth lever, supported by certification-led market access, rising demand, in-house R&D, and increasing automation.

Financial Performance Snapshot (₹ in Crore)

Strategic Expansions and Future Outlook

Cupid Limited is actively pursuing several strategic initiatives to bolster its growth trajectory. The manufacturing expansion at its Palava facility in Maharashtra is progressing as planned, aiming to significantly increase annual production capacity by approximately 770 million male condoms and 75 million female condoms. This expansion is critical to support rising volumes from both export and domestic markets.

In a significant move to strengthen its international presence, the Board has granted in-principle approval to establish an FMCG manufacturing facility in Saudi Arabia. This facility, targeted for completion by March 2027, will enhance supply responsiveness and market proximity in the GCC and Middle East regions, tapping into a growing consumer market. Furthermore, a strategic investment of ₹331.53 crore in Baazar Style Retail Limited is set to provide direct access to over 250 retail stores, projecting ₹150 crore in incremental revenue for FY27 and a ₹500 crore annual business potential within three years.

Recently, Cupid Limited also secured CE (EU IVDR) Certification for its HIV 1&2 and Hepatitis B IVD Test Kits. This certification is a meaningful step in strengthening its global diagnostics business, expanding market access to the European Economic Area and other CE-recognized markets, and enhancing eligibility for large-scale screening programs and government tenders.

Conclusion

Cupid Limited's Q3 FY26 performance reflects a company in strong operating momentum, driven by strategic expansions, diversified product offerings, and robust market penetration. The record order book and clear revenue visibility for H2 FY26 and beyond underscore management's confidence in sustained performance. With disciplined capital allocation and a focus on building a balanced, scalable, and future-ready business, Cupid Limited is well-positioned to deliver long-term value for its stakeholders, reinforcing its commitment to public health and well-being globally.